Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Non-Small-Cell Lung 545Squamous Cell Carcinoma of Head and Neck 281Head and Neck Neoplasms 258Lung Neoplasms 240Uterine Cervical Neoplasms 182Stomach Neoplasms 172Esophageal Neoplasms 161Nasopharyngeal Carcinoma 127Urinary Bladder Neoplasms 117Esophageal Squamous Cell Carcinoma 116Neoplasms 115Small Cell Lung Carcinoma 106Ovarian Neoplasms 92Breast Neoplasms 92Neoplasm Metastasis 90Cholangiocarcinoma 77Carcinoma, Squamous Cell 76Pancreatic Neoplasms 73Biliary Tract Neoplasms 72Oropharyngeal Neoplasms 57Mesothelioma, Malignant 57Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 46Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Triple Negative Breast Neoplasms 39

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Mitomycin 4Carboplatin 4Sunitinib 3Pemetrexed 3dodecyl maltoside 2cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Urologic Neoplasms × Cisplatin × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Achieve Life Sciences

Phase 2 Completed
183 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT02006667 2015-02-11

A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer

Hoffmann-La Roche

Phase 2 Completed
13 enrolled 12 charts
Genitourinary

Urologic Neoplasms

NCT00374868 2010-11-04

Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

Eli Lilly and Company

Phase 1/2 Completed
59 enrolled 17 charts
Genitourinary

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡